Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan M Weiss

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosisBrendan M Weiss, Joseph Hebreo, Daniel V Cordaro, et al.
European Journal of Haematology|June 17, 2021
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019Laura L Hester, Dina M Gifkins, Kevin M Bellew, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2016
Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantationAlex Ganetsky, Patricia A Takach, Donna-Marie Lynch, et al.
Blood|October 11, 2013
How I treat monoclonal gammopathy of renal significance (MGRS)Jean-Paul Fermand, Frank Bridoux, Robert A Kyle, et al.
Blood|September 9, 2010
Racial disparities in incidence and outcome in multiple myeloma: a population-based studyAdam J Waxman, Pamela J Mink, Susan S Devesa, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
JAMA Oncology|December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysisAdam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosisBrendan M Weiss, Joseph Hebreo, Daniel V Cordaro, et al.
European Journal of Haematology|June 17, 2021
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019Laura L Hester, Dina M Gifkins, Kevin M Bellew, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2016
Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantationAlex Ganetsky, Patricia A Takach, Donna-Marie Lynch, et al.
Blood|October 11, 2013
How I treat monoclonal gammopathy of renal significance (MGRS)Jean-Paul Fermand, Frank Bridoux, Robert A Kyle, et al.
Blood|September 9, 2010
Racial disparities in incidence and outcome in multiple myeloma: a population-based studyAdam J Waxman, Pamela J Mink, Susan S Devesa, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
JAMA Oncology|December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysisAdam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Pageof 6